Growth Outpacing Margins: A Capex Race Against Guidance
Gland delivered 23% revenue growth and 58% profit growth, but EBITDA margins missed guidance by 400 bps. The quarter reveals a company investing to scale CDMO, while Cenexi integration losses and capacity constraints postpone the profitability recovery it promised.
₹290.8 Cr
+58.3% YoY
26.4% actual
vs 30% guidance (-360 bps)
₹822.7 Cr
+31% YoY, 45% of total
-8.3%
H1 front-loaded
Where the profit came from
The headline +58% PAT growth masks two offsetting forces. Reported profit jumped to ₹290.8 Cr, but other income inflated the quarter by ₹69 Cr—mostly forex gains on the 80% export base. Stripping forex, organic profit remains healthy but the uplift is one-time. Simultaneously, Cenexi EBITDA losses (EUR 6 million in Q2 due to summer shutdowns) and elevated R&D spend (6% of revenue, up from ~4% prior) compressed margins to 26.4%, falling 360 basis points short of the 30% "near-term" guidance target.
What the numbers actually say
CDMO grew 31% YoY to ₹8.2 Cr
Transcript: ₹822.7 million (₹82.27 Cr, not ₹8.2 Cr) at 31% YoY—exact match
Supported
US business grew 42% YoY
₹1,179.5 Cr (+42% YoY); largest market, 37% of H1 revenues
Supported
EBITDA margin target 30% near-term
Q2 delivered 26-27% (reported/adjusted); gap of 300–400 bps. Not formally cut, just missed
Overstated in execution
FY27 CCy growth guidance 15%
H1 +21% YoY, Q2 +23%—on track to beat. Guidance maintained (not raised)
On track; conservative guidance
Capacity 92% utilised; new capex announced
₹10,000 Cr total capex plan (₹2k lines + ₹1k brownfield + ₹5k greenfield) from FY2030 onward
Supported; major upgrade from prior ₹2k Cr
What changed on this call
Capex bet dramatically expanded. Prior guidance: ₹2,000 Cr for India capacity additions. Now: ₹10,000 Cr total (₹2k for additional lines, ₹1k brownfield at Pashamylaram, ₹5k greenfield at Vizag SEZ), phased from FY2030 onward. This is not incremental; it signals Gland is racing to unlock capacity for CDMO and specialty injectables. Board approvals are underway.
CDMO repositioned from growth driver to core platform. Now 45% of revenue and growing at 31% YoY vs. 18% for injectables. The company disclosed a large (USD 90–100 million) CDMO contract starting CY2029, with tech transfer underway. This contract is material enough to reframe Gland's long-term profile.
Margin recovery timeline softened. Prior guidance: 30% near-term EBITDA margin. Now: delivering 26–27%, with recovery deferred to Q3+ as Cenexi normalizes. No formal cut to the 30% target, but execution reset has begun.
Leadership transition underway. New Group CEO Deepak Sapra assumes charge November 16. A management refresh amid capex execution uncertainty adds complexity.
The bull-bear ledger
Revenue growth beating guidance (23% actual vs. 15% FY27 target)
CDMO momentum real: 31% YoY growth, 45% of revenue, USD 90–100M contract visible
US business accelerating (42% YoY); largest market gaining share
FDA-cleared capacity: zero observations at Vizag, four procedural only at Dundegal
Strong balance sheet: net cash ₹32,216 Cr funds capex without strain
EBITDA margin miss: 26% vs. 30% guidance—credibility on profitability recovery now questioned
Cenexi integration losses (EUR 6M EBITDA loss Q2); profitability deferred to Q3+
QoQ PAT down 8.3% despite YoY +58%—suggests H1 front-loaded, H2 weaker
Capacity at 92% utilization; ₹10k Cr capex needed to unlock growth—execution risk high
USD 90–100M contract starts CY2029; tech transfer 2+ years away, execution dependent
Risks, ranked by holder concern
Capacity constraints & capex execution risk
HighRunning at 92% utilization; signed CDMO contracts need capacity in 2 years. ₹10k Cr greenfield is ambitious (FY2030 start, 4-year runway). Execution delays could bottleneck the USD 90–100M contract revenue inflection and force margin-dilutive subcontracting.
Cenexi integration & profitability recovery
HighLoss-making (EUR 6M EBITDA loss Q2 due to shutdowns). Prior guidance ₹200 Cr FY27 revenue at "high single-digit margin" already softened. If profitability doesn't return in Q3+, the acquisition's strategic value is questioned and cash burn continues.
EBITDA margin guidance miss & credibility
High30% near-term target; delivering 26–27% (300–400 bps gap). If H2 doesn't show recovery to 28%+, guidance credibility dents further. Analysts will demand concrete margin recovery timelines in next update.
USD 90–100M CDMO contract delayed or smaller
MediumContract is a keystone catalyst (CY2029 start; 2+ years of tech transfer). If delayed beyond CY2029 or revenue realizes lower than ₹900 Cr+ per annum, long-term 20% CAGR target becomes unachievable.
Forex volatility masking or inflating organic earnings
Medium80% export base; Q2 benefited ₹69 Cr from FX tailwinds. If USD weakens or rupee strengthens, organic profit could compress 10–15% without operational change, creating earnings whiplash.
Saudi Arabia (ROW) tender delays cascade
MediumNUPCO tender announcement still pending; ROW revenue only ₹204.4 Cr in Q2 (smallest segment). Prolonged delays risk permanent loss of market share in emerging markets.
How the street is positioned
The stock recovered powerfully from its 52-week low (₹1,573.60), now at ₹3,315 (+110.66% off the low) and trading above its 20-day, 50-day, and 200-day moving averages. However, it remains -23.79% below its all-time high of ₹4,350, suggesting the market is cautiously bullish but waiting for execution proof. RSI of 67.5 indicates neither oversold nor stretched—a NEUTRAL technical posture in an uptrend.
Institutional ownership shifted slightly: FII holding rose to 8.74% in Q1 FY27 (+1.44 percentage points from Q4), signalling foreign institutional confidence. DII trimmed to 30.44% (-2.91 percentage points), still a significant anchor. Promoter steady at 51.77%, unchanged. The FII add into a beaten-down stock suggests confidence in the long-term CDMO narrative, but DII trimming signals some caution on near-term execution.
Block activity: A recent ₹1,50,000 share transaction at ₹2,826.60 (BOA Securities Europe buying, North Rock selling) occurred at 15% below the current price, indicating this was not opportunistic selling into strength. No promoter or insider-linked activity flagged, reducing insider-concern risk.
The street's read: The stock's recovery off the low (but sustained drawdown from ATH) aligns with this quarter's mixed message: strong revenue growth and long-term optionality are priced in, but near-term margin pressure and capex execution uncertainty keep the stock from rethreading to its highs. Volume trend INCREASING suggests institutional engagement on any weakness.
The debate
The honest read: Gland is a genuine CDMO platform with real regulatory and product credentials. The long-term trajectory (35% EBITDA margin, 20% CAGR, USD 90–100M contract) is aspirational but grounded in concrete business wins. However, the near-term is messy: margins are below guidance, Cenexi integration is bleeding money, and capacity constraints require a ₹10k Cr capex bet that will defer profitability recovery by 2–3 years. The debate is whether investors should pay for long-term optionality amid near-term execution uncertainty. At ₹3,315, the stock is fairly priced for a HOLD: upside if capex executes and margins recover, downside if Cenexi turnaround slips or the USD 90–100M contract is delayed. The risk-reward is balanced; the certainty is low.
What to watch next
1 · Q3 earnings: Cenexi profitability recovery
Q3 (Oct–Dec) covers the post-summer shutdown period. If Cenexi posts break-even or low-single-digit EBITDA margins and group EBITDA margin recovers to 27–28%, the margin miss narrative reverses. This is the credibility test for guidance recovery.
2 · Capex board approval and phasing (announced in Q4 or FY28 opening)
₹10k Cr greenfield and brownfield capex needs formal board sign-off with detailed timelines, funding sources (debt vs. internal), and capacity-online dates. Details will clarify execution risk and debt trajectory.
3 · USD 90–100M CDMO contract: tech transfer progress
Management should quantify tech transfer timeline (months to validation), commercialization readiness, and any ramp assumptions. A vague contract 2+ years away is not a catalyst; a dated milestone is.
The number to track
Target: 28–30%
Q3 onwards; this is the true profitability signal
Gland Pharma delivered a quarter that separates the long-term story from near-term stumbles. Revenue growth of 23% and CDMO momentum are real, and the USD 90–100M contract is a tangible inflection point visible on the horizon. But the quarter also exposed execution gaps: margin guidance missed, Cenexi bleeding, and capex ambitions requiring a multi-year commitment. This is not a falling knife, nor is it a re-rating moment. It is a steady business investing to scale, with meaningful optionality but unproven near-term payoff.
The stock at ₹3,315 is fairly valued for a HOLD: upside on capex execution and margin recovery, downside if Cenexi delays profitability or the contract slips. Holders should expect earnings volatility (forex, Cenexi lumps) for the next 2–3 quarters. The real inflection comes in FY28–29, when capex projects stabilize and the CDMO contract ramps. Until then, watch the Q3 margin number above all else—it will tell you whether guidance is recoverable or broken.
Informational and educational content only. Not investment advice.